FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

         (Mark One)
                  X     Quarterly   Report  Pursuant  to
                           Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                       For Quarter Ended: August 31, 1998
                                       OR
                  _ Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                Georgia                                22-2408354
      (State or other jurisdiction of               (I.R.S. Employer
       incorporation or organization)              Identification No.)

          3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091-5625
           (Address of principal   executive   offices)      (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                             Yes X   No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of October 2, 1998: Common Stock, $. 10 Par Value - 7,731,818

<PAGE>


                                  IMMUCOR, INC.
                      Condensed Consolidated Balance Sheets

                                           August 31,               May 31,
ASSETS                                        1998                   1998
                                          (Unaudited)              (Audited)
                                          -------------          -------------
Current assets:
  Cash and cash equivalents                $12,700,154             $15,816,217
  Accounts receivable, net                  12,455,905              12,214,270
  Accounts receivable, other                   136,752                 695,430
  Inventories                                8,377,012               8,462,850
  Income taxes receivable                       41,079                  95,166
  Deferred income taxes                        377,875                 370,029
  Other assets                                 981,048                 447,661
                                          -------------          -------------
    Total current assets                    35,069,825              38,101,623

Long-term investment                         1,000,000               1,000,000

Property and equipment, at cost             11,119,813              10,505,766
  less accumulated depreciation             (4,282,398)             (4,486,974)
                                          -------------          --------------
                                             6,837,415               6,018,792

Other assets, net                              737,345                 801,779

Excess of cost over net tangible
  assets acquired, net                      10,987,012              11,622,082
                                          -------------          --------------

                                           $54,631,597             $57,544,276
                                          =============          ==============

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Borrowings under bank line of credit 
   agreements                                 $350,995                $359,325
  Accounts payable                           3,839,557               3,069,973
  Income taxes payable                         323,301                 359,598
  Accrued salaries and wages                   783,994                 862,550
  Other accrued liabilities                    417,768                 501,739
                                          -------------          --------------
    Total current liabilities                5,715,615               5,153,185

Long-term debt                               7,821,608               8,911,727

Deferred income taxes                        1,094,422               1,046,814

Shareholders' equity:
  Common stock, $.10 par value                 776,307                 807,881
  Additional paid-in capital                19,104,120              22,079,468
  Retained earnings                         22,565,708              21,937,697
  Accumulated other comprehensive loss      (2,446,183)             (2,392,496)
                                          -------------          --------------

    Total shareholders' equity              39,999,952              42,432,550
                                          -------------          --------------

                                           $54,631,597             $57,544,276
                                          =============          ==============

See accompanying notes.

<PAGE>


                               IMMUCOR, INC.
                Condensed Consolidated Statements of Income
                                (Unaudited)



                                                 Three Months Ended
                                           August 31,          August 31,
                                              1998                1997
                                         ----------------    ---------------


Net sales                                    $10,358,465         $9,273,479
Cost of sales                                  4,652,683          3,847,381
                                         ----------------    ---------------
Gross profit                                   5,705,782          5,426,098

Research and development                         290,027            261,299
Selling, general and administrative            4,382,663          4,160,979
                                         ----------------    ---------------
Total operating expenses                       4,672,690          4,422,278
                                         ----------------    ---------------

Income from operations                         1,033,092          1,003,820

Interest income                                  175,032            212,796
Interest expense                                (134,087)          (166,615)
Other income (expense)                            36,754            (23,098)
                                         ----------------    ---------------
Total other                                       77,699             23,083
                                         ----------------    ---------------

Income before income taxes                     1,110,791          1,026,903

Income taxes                                     482,780            469,248
                                         ----------------    ---------------

Net income                                      $628,011           $557,655
                                         ================    ===============

Earnings per share:

     Basic and diluted                             $0.08              $0.07
                                         ================    ===============


Weighted average shares outstanding:

     Basic                                     8,002,063          8,080,324
                                         ================    ===============

     Diluted                                   8,283,567          8,400,726
                                         ================    ===============



See accompanying notes.

<PAGE>


                              IMMUCOR, INC.
             Condensed Consolidated Statements of Cash Flows
                               (Unaudited)


                                                         Three Months Ended
                                                    August 31,       August 31,
                                                       1998             1997
                                                   ------------     ------------
OPERATING ACTIVITIES:
  Net income                                          $628,011         $557,655
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                                     369,761          365,201
      Amortization                                     140,496          151,725
      Changes in assets and liabilities:
        Accounts receivable                           (241,635)         119,552
        Accounts receivable, other                     558,678          (22,588)
        Income tax receivable                           54,087            2,045
        Inventories                                     85,838       (1,055,950)
        Other current assets                          (479,273)         (61,887)
        Accounts payable                               769,584          306,145
        Income taxes payable                           (36,297)          87,426
        Other current liabilities                     (114,918)         (76,869)
                                                   ------------     ------------

Cash provided by operating activities                1,734,332          372,455

INVESTING ACTIVITIES:

  Purchase of/deposits on property and equipment    (1,238,336)        (465,906)
  Decrease in other assets                                   0            4,831
                                                   ------------     ------------

Cash used in investing activities                   (1,238,336)        (461,075)

FINANCING ACTIVITIES:
  Borrowings under line of credit agreements                 0           67,147
  Repayment of notes payable                          (564,041)          (5,035)
  Exercise of stock options and warrants             1,231,444           11,250
  Purchase and retirement of stock (478,700 shares) (4,238,366)               0
                                                   ------------     ------------

Cash provided by (used in) financing activities     (3,570,963)          73,362

EFFECT OF EXCHANGE RATE CHANGES ON CASH                (41,096)        (483,303)
                                                   ------------     ------------

DECREASE IN CASH
  AND CASH EQUIVALENTS                              (3,116,063)        (498,561)

CASH AND CASH EQUIVALENTS
  AT BEGINNING OF PERIOD                            15,816,217       15,718,234
                                                   ------------     ------------

CASH AND CASH EQUIVALENTS
 AT END OF PERIOD                                  $12,700,154      $15,219,673
                                                   ============     ============



See accompanying notes.

<PAGE>

                                  IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
1998, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation  have been included.  Operating  results for the three month period
ended August 31, 1998 are not necessarily  indicative of the results that may be
expected for the year ending May 31, 1999. For further information, refer to the
consolidated   financial  statements  and  footnotes  thereto  included  in  the
Company's Annual Report on Form 10-K for the year ended May 31, 1998.

2.       INVENTORIES
Inventories are stated at the lower of first-in, first-out cost or market:

                                     As of                         As of
                                August 31, 1998                May 31, 1998
                               -----------------             ----------------
Raw materials and supplies          $2,653,718                   $2,668,444
Work in process                        726,264                      762,475
Finished goods                       4,997,030                    5,031,931
                               =================             ================
                                    $8,377,012                   $8,462,850
                               =================             ================

3.     EARNINGS PER SHARE
In 1997, the Financial  Accounting  Standards Board ("FASB") issued Statement of
Financial  Accounting  Standards No. 128, Earnings per Share ("Statement  128").
Statement 128 replaced the calculation of primary and fully diluted earnings per
share with basic and diluted  earnings per share.  Unlike  primary  earnings per
share,  basic  earnings  per share  excludes  any  dilutive  effects of options,
warrants and convertible securities.  Diluted earnings per share is very similar
to the previously  reported fully diluted  earnings per share.  All earnings per
share  amounts  for all  periods  have been  presented,  and where  appropriate,
restated to conform to the Statement 128 requirements.  The following table sets
forth the computation of basic and diluted earnings per share.

                                                         Three Months Ended
                                                    August 31,      August 31,
                                                       1998            1997
                                                   -------------  -------------
Numerator for basic and diluted earnings per share:
  Income available to common shareholders            $628,011          $557,655
                                                   =============  =============

Denominator:
  For basic earnings per share - weighted
  average basis                                       8,002,063       8,080,324

  Effect of dilutive stock options and warrants         281,504         320,402
                                                   -------------  -------------
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                    8,283,567       8,400,726
                                                   =============  =============

Basic earnings per share                                  $0.08           $0.07
                                                   =============  =============

Diluted earnings per share                                $0.08           $0.07
                                                   =============  =============
<PAGE>


4.    DOMESTIC AND FOREIGN OPERATIONS
Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):

<TABLE>
<CAPTION>
                                                          Three Months Ended August 31, 1998
                          --------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                          <C>           <C>           <C>           <C>          <C>              <C>            <C>
Net sales:
  Unaffiliated customers   $4,949        $2,422        $1,514        $1,186          $287       $     -         $10,358            
  Affiliates                  976            89             -            68             -        (1,133)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    ------------
     Total                  5,925         2,511         1,514         1,254           287        (1,133)         10,358

Income from operations        262           336           122           340             7           (34)          1,033

Identifiable assets        29,850         8,825        10,305         8,977         1,602        (4,927)         54,632

Net assets                 42,422         4,493        (1,043)        1,408           745        (8,025)         40,000

</TABLE>
<TABLE>
<CAPTION>
                                                          Three Months Ended August 31, 1997
                          --------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                          <C>           <C>           <C>           <C>          <C>              <C>            <C>
Net sales:
  Unaffiliated customers   $4,409        $2,271        $1,344        $1,071          $178       $     -          $9,273           
  Affiliates                1,053            86            18            28             -        (1,185)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    ------------
     Total                  5,462         2,357         1,362         1,099           178         1,185           9,273

Income from operations        320           220           134           340            20           (30)          1,004

Identifiable assets        31,916         8,508         9,412        10,200         1,091        (3,456)         57,671

Net assets                 44,646         3,759        (1,327)        1,233           101        (7,402)         41,010
</TABLE>


During the three  months  ended  August 31, 1998 and 1997,  the  Company's  U.S.
operation  made net export  sales to  unaffiliated  customers  of  approximately
$831,000 and $779,000,  respectively.  The Company's  German  operation made net
export  sales to  unaffiliated  customers of $288,000 and $275,000 for the three
months  ended August 31, 1998 and 1997,  respectively.  The  Company's  Canadian
operation  made  export net sales to  unaffiliated  customers  of  $811,000  and
$755,000  for the three  months  ended  August 31, 1998 and 1997,  respectively.
Product sales to affiliates are valued at market prices.

5.       COMPREHENSIVE INCOME
In June 1997, the FASB issued  Statement of Financial  Accounting  Standards No.
130, Reporting Comprehensive Income ("Statement 130"). Statement 130 establishes
new  standards for the  reporting  and display of  comprehensive  income and its
components  (revenues,  expenses,  gains,  and  losses) in a full set of general
purpose  financial  statements.  These  new  standards  require  that all  items
recognized  as  components  of  comprehensive  income be reported in a financial
statement  that is  displayed  with  the  same  prominence  as  other  financial
statements. Statement 130 is effective for fiscal years beginning after December
15,  1997.  The  Company  adopted  Statement  130 on  June 1,  1998  and has not
presented  a  statement  of  comprehensive  income  because  the  effect  of the
components of comprehensive income is not material to its consolidated financial
statements.  For the  three  months  ended  August  31,  1998  and  1997,  total
comprehensive income (loss) was $574,324 and ($222,579),  respectively, which is
comprised  of net income and other  comprehensive  losses.  Other  comprehensive
losses for the three months ended  August 31, 1998 and 1997 were  ($53,687)  and
($780,234),   respectively,   and  consisted  of  losses  on  foreign   currency
translation  adjustments.  Accumulated other comprehensive loss as of August 31,
1998 was  ($2,446,183).  The balance  consists of net losses on foreign currency
translation  adjustments  and has been  disclosed  in the  shareholders'  equity
section of the condensed consolidated balance sheet.


<PAGE>

6.   ACCOUNTS RECEIVABLE, OTHER
In fiscal 1997, Mr. Josef Wilms,  the former  president of the Company's  German
subsidiary, Immucor GmbH, borrowed, prior to his resignation,  $300,000 from the
Company at 6% interest,  secured by his warrants to purchase  143,750  shares of
the  Company's  Common  Stock.  At May 31,  1998 the loan  receivable  including
interest  totaled  $167,000,  and at August  31,  1998 the loan and all  accrued
interest was fully paid.

In July 1997,  management  of the Company  discovered  that Mr. Wilms had caused
Immucor GmbH to make unauthorized  loans to him since 1994. The amounts advanced
were documented in the records of Immucor GmbH, including interest rates ranging
from 7.75% to 9.5%, and were  generally paid down by the end of each  accounting
period,  but  were  not  disclosed  to the  Company's  management.  The  largest
aggregate  amounts  outstanding  under the  Immucor  GmbH loans were  $29,600 in
fiscal 1994,  $290,000 in fiscal 1995, $669,000 in fiscal 1996 and $1,311,000 in
fiscal 1997. At May 31, 1998 the amount receivable was approximately  $1,300,000
and at August 31, 1998 the loan receivable balance was approximately $137,000.

Mr. Wilms and his family have granted liens on certain property owned by them to
collateralize  the loans from the Company.  The Company believes it has adequate
collateral to extinguish the remaining debt and, with Mr. Wilm's assistance,  is
arranging for the liquidation of this collateral.

7.    SUBSEQUENT EVENTS
On  September  21, 1998 the Company  announced  it had entered into a definitive
merger  agreement  with Gamma  Biologicals  Inc.  under which Gamma  Acquisition
Corporation, an Immucor subsidiary, will commence a cash tender offer to acquire
all the  outstanding  shares  of Gamma  Biologicals,  Inc.  for  $5.40 per share
followed  by a  cash  merger  at  the  same  price.  The  transaction  has  been
unanimously approved by the Board of Directors of each company.  Upon completion
of the  transaction,  Gamma  Biologicals,  Inc.  will  operate as a wholly owned
subsidiary  of  Immucor,  Inc.  The cash  tender  offer of $5.40 for each  Gamma
Biologicals,  Inc. share represents a total  transaction  value of approximately
$25 million.  The tender offer is not  conditioned  upon  financing.  Subject to
satisfaction of customary closing conditions the Company expects the transaction
to close by October 23, 1998.


On September 1, 1998 the Company acquired the Canadian  distribution  rights for
the Company's  complete line of reagents from its Canadian  distributor  Immucor
Canada, Inc. for cash consideration of $1.7 million.

<PAGE>


                                  IMMUCOR, INC.

ITEM 2.  Management's  Discussion  and Analysis of Financial  Condition and
Results of Operations.

    Any  statements   contained   herein  that  are  not  historical   fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 1998.

Financial Condition and Liquidity:

    During the  quarter  the  Company  increased  its  profitability,  generated
positive cash flow from operations,  and maintained positive working capital. As
of August 31, 1998, the Company's  cash position  totaled  $12,700,154.  For the
three months ended August 31, 1998,  the Company  generated  cash from operating
activities of $1,734,332, repaid $564,041 of bank debt in Germany and Canada and
purchased  property  and  equipment  of  $1,238,336.  In June 1997,  the Company
authorized  a program to  repurchase  up to 10% of its common  stock in the open
market.  During  the three  month  period  ended  August  31,  1998 the  Company
repurchased  approximately  478,700  shares of its common  stock for  $4,238,366
under the program.  To date 582,000  shares have been  purchased  under the 1997
program.  On August 26, 1998,  the Board of Directors  authorized the Company to
repurchase up to an additional  800,000 shares of its common stock. The exercise
of approximately 163,000 stock options and warrants provided $1,231,444 in cash.

     Management  believes that the Company's  current cash and cash  equivalents
balance,  internally  generated funds, and amounts  available under the lines of
credit should be more than  sufficient to support  operations to support planned
product  introduction  and continued  improvement  and  development  of products
during the next 12 months.  Management  also  believes  additional  credit lines
would be available should the need arise for capital improvements,  acquisitions
or other corporate purposes.

Results of Operations:

Net sales

    Net sales for the three months ended August 31, 1998 totaled $10,358,465, an
increase of $1,084,986 over last year's $9,273,479.  Sales increased by $463,565
in the United States  primarily due to sales growth of  traditional  reagents to
large national buying groups.  Pursuing these groups was the Company's  strategy
to gain market share for traditional reagents and to provide the opportunity for
future instrumentation sales. These buying groups demand most favorable pricing,
and control over 80% of all purchasing decisions in the U.S. In addition,  sales
by the  Company's  Canadian and European  subsidiaries  increased  13% over last
year's  total.  The strength of the U.S.  Dollar  against most major  currencies
during the quarter as compared to the same period last year caused a decrease in
the Dollar  equivalent  product  sales  revenue.  Recorded  in their  functional
currencies,  the  increase  was 15% and was also  primarily  due to  traditional
reagent sales.

Gross profit

    As a percent of sales,  gross  profit for the three  months ended August 31,
1998  totaled  55% versus  58.5% for the same period in 1997.  In the U.S.,  the
decline  in gross  profit  margin  was  caused by  increased  national  contract
participation   and  product  mix.  In  the  Company's   European  and  Canadian
operations,  the  reduction in gross  profit  margin was  principally  caused by
increased  instrument sales. Due to the timing of the sales, the Company has not
recognized the full benefit of the associated reagent sales during this quarter.
The  Company  expects  increased  reagent  sales in future  quarters  due to the
placement of these  instruments  which will  positively  affect the gross profit
margin.



<PAGE>

Operating expenses

    As compared to the prior year,  research  and  development  costs  increased
$28,728  for  the  three  month  period  due  to  increased  instrument  related
development costs.

    Selling,  general and  administrative  expenses  increased  $221,684 for the
three month  period as compared  to the same period last year.  The  increase is
primarily  due to  the  effect  of  higher  payroll  expense  due to  additional
personnel required for the Company's instrumentation strategy.

Interest income

    Interest income decreased $37,764 for the quarter due to lower cash balances
as compared to last year.

Interest expense

    When  compared  to the prior  year  three  month  period,  interest  expense
declined  $32,528  which was caused by the repayment of bank debt in Germany and
Canada.

Other income(expense)

    Other income  increased  for the three month period as compared to the prior
year due to a gain on sale of certain assets in Europe during the current period
compared to higher currency transaction losses incurred in Europe last year.

Income taxes

    Income tax expense as a percent of pretax income, decreased during the three
month  period  ended  August 31, 1998 due to lower taxes  provided in Germany as
compared to the prior period as a result of the Company's ongoing implementation
of tax planning strategies.

Year 2000

     The  Company is aware of the issues  that many  companies  will face as the
year 2000  approaches.  In order to become year 2000 compliant,  the Company has
set up a project team to address the issue and has taken the following steps:

    Impact  Assessment-  Instances where electronics are used in the Company and
the associated  potential risks have been identified.  The Company believes that
non-information  technology  systems  and its  products  are  not  significantly
impacted.  However,  internal business information software is affected and will
require program changes in order to become year 2000 compliant.

    Third  Party  Impact  Assessment  - The  Company  has  begun to  verify  the
readiness of its significant suppliers and customers through the distribution of
a  questionnaire.  Although this process is not complete,  based on  information
available,  the  Company  has no reason to believe  that any year 2000  problems
encountered  by customers  and suppliers  will have a significant  effect on the
Company's  operations.  The  Company  estimates  that  this  assessment  will be
completed by February 1999.




<PAGE>

    Project  Plan - Based on the impact  assessment,  the need to make  software
program changes to the Company's internal business information software has been
identified.  In Europe,  minor software  program changes to existing systems are
being made at a nominal cost making them year 2000  compliant  before the summer
of 1999. In North America,  since the Company had already planned to implement a
new enterprise wide internal business  information  software system by September
1999, the need to make software  changes to the existing system are for the most
part not required.  The Company is currently  identifying which software package
to implement  and ensuring that the system is year 2000  compliant.  The Company
had originally  planned to identify a software package by September 1998 and has
decided  to  delay  the  decision   until  November  1998  due  to  a  potential
acquisition.   This  delay  has  caused  the   rescheduling   of  the  Company's
implementation  plan. The software should be installed by February 1999,  tested
and modified by October 1999 and be operating by November 1999. The Company will
set  milestone  completion  dates  during the  implementation  period of the new
software and be monitoring progress closely.

     Contingency  Plan  -  The  risk  the  Company  faces  is  a  delay  in  the
implementation of the new internal business information software. The Company is
uncertain what the costs  associated with a delay would be or the related impact
on operations,  liquidity and financial condition.  Because of this, the Company
has in  place  a  contingency  plan  which  would  be  put  into  effect  should
implementation milestones not be met. If by April 1999, it is determined that an
October testing and modification milestone cannot be completed, the Company will
begin to make program  modifications to the existing internal business software.
The Company estimates that all modifications and testing can be completed within
two months at a cost of less than  $20,000  which will be expensed as  incurred.
Expenses to date are nominal.

    The Company  believes that it is diligently  addressing  the year 2000 issue
and expects  that  through its actions  year 2000  problems  are not  reasonably
likely to have a material adverse effect on the Company's operations.  There can
be no assurance that such problems will not arise.

<PAGE>

PART 11 - OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

         27 Financial data schedule.

         (b) The  Company  did not file any reports on Form 8-K during the three
         months ended August 31, 1998.

<PAGE>

                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                  IMMUCOR, INC.
                                  (Registrant)



Date:  October 13, 1998








Edward L. Gallup               Edward L. Gallup, President








Steven C. Ramsey               Steven C. Ramsey, Senior Vice President - Finance
                                            (Principal Accounting Officer)